Search results
Results from the WOW.Com Content Network
While many treatments appear to improve biochemical markers such as alanine transaminase levels, most do not reverse histological abnormalities or improve outcomes. [ 5 ] [ 14 ] [ 103 ] [ needs update ] Treatment with medications is primarily aimed at improving liver disease and is generally limited to those with biopsy-proven NASH and fibrosis.
Like many cancers, treatment depends on the specific type of liver cancer as well as stage of the cancer. The main way cancer is staged is based on the TMN staging systems. There are also liver cancer specific staging systems, each of which has treatment options that may result in a non recurrence of cancer, or cure.
Level of the biomarker should not change spontaneously or in response to other factors not related to the successful treatment of the cancer; Two areas in particular that are receiving attention as surrogate markers include circulating tumor cells (CTCs) [45] [46] and circulating miRNAs.
For premium support please call: 800-290-4726 more ways to reach us
As with any cancer, the treatment and prognosis of HCC varies depending on tumor histology, size, how far the cancer has spread, and overall health of the person. The vast majority of HCC cases and the lowest survival rates after treatment occur in Asia and sub-Saharan Africa , in countries where hepatitis B infection is endemic and many are ...
The level of tumor marker should indicate the state of the malignancy to be able to monitor treatment response. An ideal tumor marker does not exist, and how they are clinically applied depends on the specific tumor marker. For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give ...
Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease. [1] [2] [3] [4]
NASH was first described in 1980 in a series of patients of the Mayo Clinic. [7] Its relevance and high prevalence were recognized mainly in the 1990s. Some think NASH is a diagnosis of exclusion, and many cases may in fact be due to other causes. [8]